BioInnovation Institute (BII) joins the global CARB-X network to accelerate start-ups in drug-resistant infections
An estimated 700,000 people die each year worldwide from bacterial infections. New antibiotics, rapid diagnostics, vaccines and other products are urgently needed to treat bacteria that are increasingly resistant to existing antibiotics. This is the challenge adressed by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which is now expanding its Global Accelerator Network to include among others BII.
“By joining the network, BioInnovation Institute commits to support international CARB-X companies in their development through Phase 1. At BioInnovation Institute, they will have access to our 2300 m2 state-of-the-art labs and office space, high-level mentors and experts, a thriving entrepreneurial community and networks in the heart of Medicon Valley, one of Europe’s leading life science clusters,” says Jens Nielsen, CEO at BioInnovation Institute.
The first CARB-X BioInnovation Institute collaborations are expected to start in the summer of 2019. Read full article in today´s online edition of “European Biotechnology“.